HELX Holdings — Franklin Genomic Advancements ETF
All 63 reported holdings of Franklin Genomic Advancements ETF (HELX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Guardant Health, Inc. | 9.09% | $2.54M |
| Natera, Inc. | 7.46% | $2.08M |
| Krystal Biotech, Inc. | 6.33% | $1.77M |
| Ligand Pharmaceuticals, Inc. | 4.62% | $1.29M |
| Adaptive Biotechnologies Corp. | 3.99% | $1.11M |
| United Therapeutics Corp. | 3.51% | $980.17K |
| Bridgebio Pharma, Inc. | 3.50% | $977.85K |
| Eli Lilly & Company | 2.95% | $825.21K |
| Twist Bioscience Corp. | 2.85% | $795.88K |
| Vertex Pharmaceuticals, Inc. | 2.75% | $767.45K |
| Astrazeneca PLC | 2.70% | $754.50K |
| Travere Therapeutics, Inc. | 2.59% | $724.50K |
| Insmed, Inc. | 2.44% | $681.09K |
| Samsung Biologics Co. Ltd. | 2.26% | $630.27K |
| Corteva, Inc. | 2.25% | $629.67K |
| Medpace Holdings, Inc. | 2.15% | $600.03K |
| Alnylam Pharmaceuticals, Inc. | 1.96% | $546.67K |
| Tempus Ai, Inc. | 1.95% | $544.37K |
| Ionis Pharmaceuticals, Inc. | 1.91% | $534.34K |
| Neurocrine Biosciences, Inc. | 1.84% | $515.38K |
| Regeneron Pharmaceuticals, Inc. | 1.80% | $501.95K |
| Veracyte, Inc. | 1.64% | $459.21K |
| Argenx SE | 1.64% | $458.27K |
| Ptc Therapeutics, Inc. | 1.46% | $408.58K |
| Biontech SE | 1.38% | $386.72K |
| Stoke Therapeutics, Inc. | 1.33% | $371.34K |
| Charles River Laboratories International, Inc. | 1.26% | $352.89K |
| Grail, Inc. | 1.09% | $304.21K |
| Anaptysbio, Inc. | 1.04% | $289.57K |
| Crispr Therapeutics AG | 0.98% | $274.34K |
| Repligen Corp. | 0.98% | $274.11K |
| Cadence Design Systems, Inc. | 0.97% | $272.11K |
| Beam Therapeutics, Inc. | 0.93% | $260.04K |
| Praxis Precision Medicines, Inc. | 0.86% | $240.38K |
| Sartorius AG | 0.85% | $237.56K |
| Axsome Therapeutics, Inc. | 0.82% | $229.10K |
| Caredx, Inc. | 0.82% | $228.00K |
| Jazz Pharmaceuticals PLC | 0.78% | $218.08K |
| Catalyst Pharmaceuticals, Inc. | 0.77% | $215.77K |
| Thermo Fisher Scientific, Inc. | 0.76% | $211.07K |
| Iqvia Holdings, Inc. | 0.75% | $209.06K |
| Hinge Health, Inc. | 0.70% | $194.97K |
| Ultragenyx Pharmaceutical, Inc. | 0.61% | $171.32K |
| Agilent Technologies, Inc. | 0.58% | $162.45K |
| Danaher Corp. | 0.57% | $160.38K |
| Qiagen NV | 0.48% | $133.68K |
| Rhythm Pharmaceuticals, Inc. | 0.42% | $116.36K |
| Arcutis Biotherapeutics, Inc. | 0.41% | $115.94K |
| Samsung Epis Holdings Co. Ltd. | 0.37% | $104.36K |
| Kiniksa Pharmaceuticals International PLC | 0.34% | $94.58K |
| Tarsus Pharmaceuticals, Inc. | 0.26% | $71.50K |
| Bio-Rad Laboratories, Inc. | 0.26% | $71.35K |
| Liquidia Corp. | 0.25% | $69.44K |
| Bristol-Myers Squibb Company | 0.25% | $68.91K |
| Tg Therapeutics, Inc. | 0.25% | $68.84K |
| Beone Medicines Ltd. | 0.23% | $64.12K |
| Neurogene, Inc. | 0.22% | $62.30K |
| First Tracks Biotherapeutics, Inc. | 0.20% | $55.83K |
| Genedx Holdings Corp. | 0.14% | $39.47K |
| Wave Life Sciences Ltd. | 0.10% | $27.96K |
| Recursion Pharmaceuticals, Inc. | 0.07% | $20.21K |
| Omniab, Inc. | 0.00% | $0 |
| Omniab, Inc. | 0.00% | $0 |
HELX overview: performance, fees, allocation and SEC filings